Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.75 Contact Hours.
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Tesaro Inc.
Release Date: March 30, 2018
Expiration Date: March 30, 2019
Media: Internet - based
Immunotherapy options for patients with cancer are increasing rapidly, shaping the treatment landscape for patients with a variety of different malignancies. This online activity features an expert panel of oncologists who will discuss recent advancements in the field of immunotherapy, highlighting noteworthy data presented at major society meetings in 2017. Each module will focus on a different component of immunotherapy and its growing impact in cancer care. Topics will include advancements in the understanding of immunotherapy mechanisms and tumor biology, the exploration of prognostic markers to personalize immunotherapy utilization, an analysis of key safety and efficacy data from recent clinical trials of immunotherapy, and a look ahead at ongoing immunotherapy studies for patients with cancer.
Our panel of experts will provide clinical insight into the implications of recent immunotherapy-related data, review the potential application of these data, and discuss the future direction of immunotherapy strategies for patients with cancer.
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, and Tesaro Inc.
Instructions for This Activity and Receiving Credit
This educational activity is directed toward medical oncologists, surgical oncologists, radiation oncologists, and pulmonologists involved in the treatment and management of patients with cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals (HCPs) interested in the treatment of cancer are also invited to participate.
At the conclusion of this activity, you should be better prepared to:
Naiyer A. Rizvi, MD
Professor of Medicine
Director, Thoracic Oncology
Co-Director, Cancer Immunotherapy Program
Price Chair in Clinical Translational Research
Columbia University Medical Center
New York, NY
Disclosure: Consultant: Roche, AstraZeneca, Novartis, Merck, Lilly, Bristol-Myers Squibb, Pfizer, Gritstone Oncology, ARMO Biosciences
Ezra Cohen, MD, FRCPSC, FASCO
Professor, Division of Hematology/Oncology, Department of Medicine
University of California, San Diego
Associate Director for Translational Science, Moores Cancer Center
Director, Cancer Immunotherapy, Moores Cancer Center
Co-Leader, Solid Tumor Therapeutics Program
Co-Director, Head and Neck Cancer Center of Excellence
San Diego, CA
Disclosure: Research Grants: AstraZeneca/MedImmune, Bristol-Myers Squibb, Clovis, Genentech, Johnson & Johnson, Lilly, Merck, Novartis; Consultant: Ariad, AstraZeneca, Bayer, Boehringer Ingelheim, Celgene, Clovis, Genentech, Guardant Health, Lilly, Liquid Genomics, Merck, Mirati, Novartis, Peregrine, Pfizer, Roche Diagnostics, Synta, Trovagene
Susan F. Slovin, MD, PhD
Genitourinary Oncology Service
Sidney Kimmel Center for Prostate and Urologic Cancers
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosure: No relevant financial relationships with commercial interests to disclose.
The staff of PER® have no relevant financial relationships with commercial interests to disclose.
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
Oncology Briefings™: Updates in Therapeutic Options and Approaches for Tenosynovial Giant Cell Tumors
Apr 28, 2018
April 28, 2018
New York, NY